Evetifator

CAS 2278265-85-1

MF C20H19ClF3N3O4 MW457.8 g/mol

2-(4-chlorophenoxy)-N-[3-[5-[3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamide

2-(4-chlorophenoxy)-N-(3-{5-[(1s,3s)-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl}bicyclo [1.1.1]pentan-1-yl)acetamide
eukaryotic translation initiation factor 2B (eIF2B) activator, DNL-343, DNL 343, FYL3Y9D7SK

Evetifator (also known as DNL343) is a potent, selective, and brain-penetrant small molecule activator of eukaryotic initiation factor 2B (eIF2B). As of 2026, it is primarily being investigated for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). 

Key Characteristics and Function 

• Mechanism of Action: It acts as an eIF2B activator. eIF2B is a critical regulator of protein synthesis; by activating it, the drug aims to address the Integrated Stress Response (ISR) which, when chronically activated, leads to neurodegeneration.
• Pharmacological Profile:
  • Potency: It shows an IC50cap I cap C sub 50𝐼𝐶50 of 3.2 nM in cellular reporter assays.
  • Brain Penetration: It is specifically designed to cross the blood-brain barrier to target the central nervous system (CNS).

• A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy VolunteersCTID: NCT04581772Phase: Phase 1Status: CompletedDate: 2021-06-11
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy VolunteersCTID: NCT04268784Phase: Phase 1Status: CompletedDate: 2022-02-07
• HEALEY ALS Platform Trial – Regimen G DNL343CTID: NCT05842941Phase: Phase 2/Phase 3Status: CompletedDate: 2025-02-04
• A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral SclerosisCTID: NCT05006352Phase: Phase 1Status: CompletedDate: 2024-09-19
• HEALEY ALS Platform Trial – Master ProtocolCTID: NCT04297683Phase: Phase 2/Phase 3Status: Active, not recruitingDate: 2025-12-31

SYN

WO 2019/032743

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019032743&_cid=P10-MKOU1U-66006-1

EXAMPLE 3

2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1- bicyclo[1.1.1]pentanyl]acetamide

[0257] 2-(4-chlorophenoxy)-N-[1-(hydrazinecarbonyl)-3-bicyclo[1.1.1]pentanyl]acetamide (200 mg, 0.65 mmol), 3-cis-(trifluoromethoxy)cyclobutanecarboxylic acid (131 mg, 0.71 mmol; 8:1 to 10:1 ratio of cis- to trans-) and triethylamine (NEt₃) (0.45 mL, 3.23 mmol) were dissolved in EtOAc (2.6 mL) and T3P solution (0.58 mL, 1.94 mmol, 50 % in EtOAc) was added. The resulting reaction mixture was heated to 100 °C overnight, cooled to rt and was diluted with sat. aq. NaHCO₃ solution (10 mL) and EtOAc (10 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The crude reaction mixture was purified employing reverse-phase prep-HPLC to deliver the desired product as a clear oil. ¹H-NMR (400 MHz; CDCl₃): δ 7.33-7.29 (m, 2H), 7.03 (s, 1H), 6.91-6.87 (m, 2H), 4.76-4.69 (m, 1H), 4.44 (s, 2H), 3.39-3.30 (m, 1H), 2.92-2.84 (m, 2H), 2.74-2.68 (m, 2H), 2.67 (s, 6H). LC-MS m/z: = 458.20 [M+H]⁺.

[0258] Alternatively, a mixture of 2-(4-chlorophenoxy)acetic acid (50 mg, 0.27 mmol), 2-(4-chlorophenoxy)acetic acid (50 mg, 0.27 mmol), NEt₃ (123 mg, 1.21 mmol) and T3P (185 mg, 0.29 mmol, 50% purity) in DCM (1 mL) was stirred at 0 °C for 1 h. To the mixture was added 1-[5-[3-cis-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]bicyclo[1.1.1]pentan-3-amine HCl salt (8:1 to 10:1 favoring the cis- diastereomer) (70 mg, 0.24 mmol) at 0 °C. The mixture was stirred at 25 °C for 12 h. To the reaction was added sat. aq. NaHCO₃ (4 mL). The aqueous phase was extracted with DCM (5 mL, 3 mL). The combined organic phase was washed with brine (10 mL), dried with anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to provide the title compound.

SYN

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022133236&_cid=P10-MKOTTO-58939-1

2-(4-chlorophenoxy)-N-[3-[5-[cA-3-(trifluoromethoxy)cyclobutyl]-l,3,4-oxadiazol-2-yl]-l-bicyclo[l.l.l]pentanyl]acetamide, designated herein as Compound I, has the following formula:

Example 1. Synthesis of Compound I

2-(4-chlorophenoxy)-/V-[l-(hydrazinecarbonyl)-3-bicyclo[l.l.l]pentanyl]acetamide

[0131] To a suspension of methyl 3-[[2-(4-chlorophenoxy)acetyl]amino]bicyclo[l.l.l]pentane-l-carboxylate (270 mg, 0.87 mmol) in EtOH (0.25-0.1M) was added hydrazine hydrate (131 mg, 2.6 mmol) in EtOH (3.5 mL) and the reaction mixture was heated at 90 °C overnight. The reaction mixture

was cooled to rt often causing the product to crystallize out of solution. This solid was collected by removal of the supernatant. If the product did not crystallize, the solution was concentrated, and the crude product was sufficiently pure to use in subsequent steps.

LC-MS m/z: = 310.1 [M+H]⁺.

2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamide

[0132] 2-(4-chlorophenoxy)-N-[1-(hydrazinecarbonyl)-3-bicyclo[1.1.1]pentanyl]acetamide (200 mg, 0.65 mmol), 3-cis-(trifluoromethoxy)cyclobutanecarboxylic acid (131 mg, 0.71 mmol; 8:1 to 10:1 ratio of cis- to trans-) and triethylamine (NEt₃) (0.45 mL, 3.23 mmol) were dissolved in EtOAc (2.6 mL) and T3P solution (0.58 mL, 1.94 mmol, 50 % in EtOAc) was added. The resulting reaction mixture was heated to 100 ºC overnight, cooled to rt and was diluted with sat. aq. NaHCO₃ solution (10 mL) and EtOAc (10 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The crude reaction mixture was purified employing reverse-phase prep-HPLC to deliver the desired product as a clear oil.¹H-NMR (400 MHz; CDCl₃): δ 7.33-7.29 (m, 2H), 7.03 (s, 1H), 6.91-6.87 (m, 2H), 4.76-4.69 (m, 1H), 4.44 (s, 2H), 3.39-3.30 (m, 1H), 2.92-2.84 (m, 2H), 2.74-2.68 (m, 2H), 2.67 (s, 6H). LC-MS m/z: = 458.20 [M+H]⁺.

[0133] Alternatively, a mixture of 2-(4-chlorophenoxy)acetic acid (50 mg, 0.27 mmol), NEt3 (123 mg, 1.21 mmol) and T3P (185 mg, 0.29 mmol, 50% purity) in DCM (1 mL) was stirred at 0 °C for 1 h. To the mixture was added 1-[5-[3-cis-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]bicyclo[1.1.1]pentan-3-amine HCl salt (8:1 to 10:1 favoring the cis- diastereomer) (70 mg, 0.24 mmol) at 0 °C. The mixture was stirred at 25 °C for 12 h. To the reaction was added sat. aq. NaHCO3 (4 mL). The aqueous phase was extracted with DCM (5 mL, 3 mL). The combined organic phase was washed with brine (10 mL), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide the title compound.

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023250107&_cid=P10-MKOTXL-62392-1

Example 14: Preparation of 2-(4-chlorophenoxy)-N-(3-(5-((ls,3s)-3-(trifluoromethoxy)cyclobutyl)- l,3,4-oxadiazol-2-yl)bicyclo[l.l.l]pentan-l-yl)acetamide (I)

[0377] XI- la, 2-(4-chlorophenoxy)acetic acid (XII- la), and 2-MeTHF were charged to a reactor under N2 condition and cooled to 0 ~ 5 °C. TEA was added while maintaining an internal temperature of not more than about 10 °C under N2 condition and rinsed with 2-methyltetrahydrafuran (2-MeTHF). The contents were agitated at about 0 ~ 5 °C for not less than about 20 minutes. Diphenylphosphinic chloride in 2-MeTHF solution is added slowly while maintaining an internal temperature of not more than about 10 °C under N2 condition and rinsed with 2-MeTHF. The contents were warmed to about 20 ~ 25 °C and then agitated for not less than about 1 hour until the reaction was completed. The contents were cooled to about 0 ~ 5 °C and then aqueous 10% K2CO3 was added while maintaining an internal temperature of not more than about 10 °C. After phase separation, the organic layer was successively washed with aqueous 10% K2CO3 and 5% K2CO3. The organic layer was concentrated to a target volume 3 V. 2-MeTHF was added and then the contents were concentrated to a target volume 3 V to control the water content to not more than about 0.3 w/w%. IPA was added and then the contents were heated to about 60 ~ 70 °C to

dissolve all solids. The contents were filtered at about 60 ~ 70 °C through cartridge filter and rinsed with pre-heated IPA (60 ~ 70 °C). The filtrate was concentrated to a target volume 4 V. IPA was added and concentrated to a target volume 4 V to control the residual 2-MeTHF relative to IPA to not more than 1 % by GC. The contents were adjusted to about 20 ~25 °C. n-Heptane was added and then heated to about 60 ~ 80 °C to dissolve all solids. The contents were adjusted to about 62 ~ 70 °C. Seed crystal was charged and agitated for not less than about 0.5 hour. n-Heptane was added while maintaining an internal temperature of about 60 ~ 65 °C. The contents were cooled to about 0 ~ 5 °C over 12 hour (5 °C per hour). The slurry was agitated for not less than 2 hours. The slurry was filtered and washed with precooled IPA/n-heptane mixture. The wet cake was dried at 25 °C under vacuum. If any individual impurity except 2-(4-chlorophenoxy)-N-(3-(5-(trans-3-(trifluoromethoxy)cyclobutyl)-l,3,4-oxadiazol-2-yl)bicyclo[l.l.l]pentan-l-yl)acetamide was more than 0.12%, recrystallization was performed.

[0378] ’H NMR (600 MHz, MeCN-d₃): 7.65 (s, 1H), 7.3

PAT

• Compounds, compositions and methodsPublication Number: JP-2023052166-APriority Date: 2017-08-09
• Compounds, compositions, and methodsPublication Number: CN-111094233-BPriority Date: 2017-08-09Grant Date: 2024-03-15
• Modulators of eukaryotic initiation factor 2B, compositions and methodsPublication Number: US-11236100-B2Priority Date: 2017-08-09Grant Date: 2022-02-01
• Compounds, compositions, and methodsPublication Number: CN-118239938-APriority Date: 2017-08-09
• Solid forms of a compoundPublication Number: US-2024059662-A1Priority Date: 2020-12-18
• Modulators of eukaryotic initiation factor 2B, compositions and methodsPublication Number: US-2022411433-A1Priority Date: 2017-08-09
• COMPOUNDS, COMPOSITIONS AND METHODSPublication Number: WO-2019032743-A1Priority Date: 2017-08-09
• Modulators of eukaryotic initiation factor 2B, compositions and methodsPublication Number: US-11851440-B2Priority Date: 2017-08-09Grant Date: 2023-12-26
• Compounds, compositions and methodsPublication Number: US-2021147435-A1Priority Date: 2017-08-09

AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

……

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

//////evetifator, ANAX, eukaryotic translation initiation factor 2B (eIF2B) activator, DNL-343, DNL 343, FYL3Y9D7SK